The Cancer DNA Screening Pilot Study (CANDACE) has been approved to recruit eligible participants from the BC Cancer Agency's BC Generations Project cohort to assess the usefulness of an experimental new technology.
Most population-based cancer screening methods (e.g. mammography or colonoscopy) only search for a single type of cancer. Other methods that could detect a number of different cancers during a single screening – such as MRI – are too costly and invasive for routine, widespread use.
The study will assess the clinical utility of Pathway Genomics
test. Based on a technology developed by Boreal Genomics
, this experimental test uses blood samples to identify mutations in genes that are associated with the development and progression of cancer.
The CANDACE study has been approved to recruit eligible participants from the BC Generations Project cohort. Project participants who meet the study criteria will be contacted by the BC Generations Project and invited to participate. As always, participation is completely voluntary. Participation in this study is by invitation only.
The study aims to recruit 1,000 healthy volunteer participants who have not been diagnosed with cancer in the past. Participants who have a positive test result will be examined further using standard-of-care diagnostic methods (e.g. medical imaging) to confirm whether the blood test has correctly indicated the presence of a cancer.
The CANDACE study is led by the BC Cancer Agency in collaboration with the University of British Columbia
, Boreal Genomics, the BC Generations Project and Pathway Genomics.